KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Non-Current Liabilities: 2019-2023

Historic Other Non-Current Liabilities for Esperion Therapeutics (ESPR) over the last 5 years, with Dec 2023 value amounting to $239.9 million.

  • Esperion Therapeutics' Other Non-Current Liabilities was N/A to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year change of. This contributed to the annual value of $239.9 million for FY2023, which is 9.64% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Other Non-Current Liabilities of $239.9 million as of FY2023, which was up 9.64% from $218.8 million recorded in FY2022.
  • Esperion Therapeutics' Other Non-Current Liabilities' 5-year high stood at $245.7 million during FY2021, with a 5-year trough of $127.3 million in FY2019.
  • For the 3-year period, Esperion Therapeutics' Other Non-Current Liabilities averaged around $234.8 million, with its median value being $239.9 million (2023).
  • In the last 5 years, Esperion Therapeutics' Other Non-Current Liabilities surged by 43.53% in 2021 and then dropped by 10.95% in 2022.
  • Esperion Therapeutics' Other Non-Current Liabilities (Yearly) stood at $127.3 million in 2019, then spiked by 34.49% to $171.2 million in 2020, then soared by 43.53% to $245.7 million in 2021, then fell by 10.95% to $218.8 million in 2022, then increased by 9.64% to $239.9 million in 2023.